Immutep Ltd ADR (IMMP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.29 (-9.72%), Market cap $0.07B, 52-week low–high $0.31 ~ $3.18.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinom
Financial statements, price targets, institutional (13F) holdings and related news for Immutep Ltd ADR are updated in real time on BlackAll Trade.
Immutep Ltd ADR trades at $0.29 (-9.72%). Real-time quotes and charts are available on BlackAll Trade.
Immutep Ltd ADR has a market cap of about $0.07B.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate i